● Recruiting

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

Condition: Gastric or Gastroesophageal Junction Adenocarcinoma · Pancreatic Ductal Adenocarcinoma · Biliary Tract Cancer (BTC) · Sponsor: Phanes Therapeutics

PhasePhase 1/Phase 2

Planned participants258

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This is a first-in-human, Phase 1/2, open-label, dose escalation and dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Spevatamig (PT886). Patients with the following tumor types will be eligible for screening: unresectable or metastatic gastric adenocarcinoma, gastroesophageal junction (GEJ) adenocarcinoma, biliary tract carcinoma (BTC) and pancreatic ductal adenocarcinoma (PDAC).

This description comes directly from the study's public registry record.

Talk to the study team

Phanes Therapeutics · 858-766-0852 · clinical-trials@phanestx.com

Always discuss trial participation with your own doctor first.

Locations (11)

City of Hope (City of Hope National Medical Center, City of Hope Medical Center)	Duarte, California, United States	Recruiting
USC Norris Comprehensive Cancer Center	Los Angeles, California, United States	Recruiting
Sarah Cannon Research Institute (SCRI)	Denver, Colorado, United States	Recruiting
University of Iowa	Iowa City, Iowa, United States	Recruiting
Norton Cancer Institute	Louisville, Kentucky, United States	Recruiting
Dana-Farber Cancer Institute (DFCI)	Boston, Massachusetts, United States	Active Not Recruiting
Duke Cancer Center	Durham, North Carolina, United States	Recruiting
University of Pittsburgh Medical Center (UPMC)	Pittsburgh, Pennsylvania, United States	Recruiting
MD Anderson Cancer Center, GI Medical Oncology Dept	Houston, Texas, United States	Recruiting
NEXT Oncology	Fairfax, Virginia, United States	Recruiting
University of Wisconsin Carbone Cancer Center - University Hospital	Madison, Wisconsin, United States	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05482893